Year Year arrow
arrow-active-down-0
Publisher Publisher arrow
arrow-active-down-1
Journal
1
Journal arrow
arrow-active-down-2
Institution Institution arrow
arrow-active-down-3
Institution Country Institution Country arrow
arrow-active-down-4
Publication Type Publication Type arrow
arrow-active-down-5
Field Of Study Field Of Study arrow
arrow-active-down-6
Topics Topics arrow
arrow-active-down-7
Open Access Open Access arrow
arrow-active-down-8
Language Language arrow
arrow-active-down-9
Filter Icon Filter 1
Year Year arrow
arrow-active-down-0
Publisher Publisher arrow
arrow-active-down-1
Journal
1
Journal arrow
arrow-active-down-2
Institution Institution arrow
arrow-active-down-3
Institution Country Institution Country arrow
arrow-active-down-4
Publication Type Publication Type arrow
arrow-active-down-5
Field Of Study Field Of Study arrow
arrow-active-down-6
Topics Topics arrow
arrow-active-down-7
Open Access Open Access arrow
arrow-active-down-8
Language Language arrow
arrow-active-down-9
Filter Icon Filter 1
Export
Sort by: Relevance
  • Research Article
  • Cite Count Icon 63
  • 10.33321/cdi.2000.24.65
Murray Valley encephalitis in Western Australia in 2000, with evidence of southerly spread.
  • Sep 25, 2024
  • Communicable diseases intelligence
  • S P Cordova + 5 more

We describe the epidemiological and clinical features of human Murray Valley encephalitis (MVE) and Kunjin (KUN) virus infections in Western Australia (WA) during March to July 2000. A case series was performed. For laboratory-confirmed cases, travel histories and clinical details were collected from patients, family members, friends or treating physicians. Surveillance data from the sentinel chicken program and climatic conditions were reviewed. Nine encephalitic cases of MVE were recorded. Eight were non-Aboriginal adults (age range, 25 to 79 years; 5 male, 3 female) and 1 was an Aboriginal boy. Four cases acquired infection in the Murchison and Midwest regions of WA from which no human cases of MVE have been reported previously. One of the 9 cases was fatal and 3 had severe neurological sequelae. Five non-encephalitic infections were also recorded, 3 MVE and 2 KUN. Encephalitis caused by MVE virus remains a serious problem with no improvement in clinical outcomes in the last 25 years. Excessive rainfall with widespread flooding in the northern two-thirds of WA provided ideal conditions for mosquito breeding and favoured southerly spread of the virus into new and more heavily populated areas. Surveillance in WA with sentinel chickens and mosquito trapping needs expansion to define the boundaries of MVE virus activity. To enable timely warnings to the public, and to institute mosquito control where feasible, continued surveillance in all Australian areas at risk is indicated.

  • Research Article
  • 10.33321/cdi.2000.24.2
Communicable diseases surveillance
  • Sep 11, 2024
  • Communicable diseases intelligence
  • No Authors Listed

Communicable diseases surveillance outcomes from several reporting series as follows: Communicable Diseases Surveillance: Highlights, December 1999 (vaccine preventable diseases, vectorborne diseases, gastrointestinal diseases, other);National Notifiable Diseases Surveillance System tables, 8 December 1999 to 4 January 2000;Laboratory Serology and Virology Reporting Scheme tables, 2 to 29 December 1999;Australian Sentinel Practice Research Network report tables, weeks 49 to 51, 1999;Gonococcal surveillance, reporting period 1 April to 30 June 1999;Australian encephalitis: chicken surveillance program, reporting period September and October 1999;HIV and AIDS surveillance, reporting period 1 to 31 August 1999, assessed as at 30 November 1999.

  • Research Article
  • 10.33321/cdi.2024.48.15
Australian Gonococcal Surveillance Programme, 1 October to 31 December 2023
  • May 13, 2024
  • Communicable Diseases Intelligence
  • Monica M Lahra + 2 more

The Australian National Neisseria Network (NNN) comprises reference laboratories in each state and territory that report data on antimicrobial susceptibility testing to an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). The AGSP data are presented quarterly in tabulated form, as well as in the AGSP annual report. This report presents national gonococcal antimicrobial resistance surveillance data from 1 October to 31 December 2023

  • Research Article
  • 10.33321/cdi.2024.48.21
Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2023
  • May 13, 2024
  • Communicable Diseases Intelligence
  • Monica M Lahra + 1 more

The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.

  • Research Article
  • 10.33321/cdi.2024.48.22
Meningococcal Surveillance Australia: Reporting period 1 July to 30 September 2023
  • May 13, 2024
  • Communicable Diseases Intelligence
  • Monica M Lahra + 1 more

The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.

  • Research Article
  • 10.33321/cdi.2024.48.23
Meningococcal Surveillance Australia: Reporting period 1 October to 31 December 2023
  • May 13, 2024
  • Communicable Diseases Intelligence
  • Monica M Lahra + 1 more

The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.

  • Research Article
  • Cite Count Icon 2
  • 10.33321/cdi.2024.48.10
COVID-19 Australia: Epidemiology Report 84: Reporting period ending 11 February 2024.
  • Apr 23, 2024
  • Communicable Diseases Intelligence
  • Viral Respiratory Diseases Epidemiology And Surveillance Team

This is the eighty-fourth epidemiological report for coronavirus disease 2019 (COVID-19), reported in Australia as at 23:59 Australian Eastern Daylight Time [AEST] 11 February 2024. It includes data on COVID-19 cases diagnosed in Australia.

  • Research Article
  • Cite Count Icon 2
  • 10.33321/cdi.2024.48.11
COVID-19 Australia: Epidemiology Report 85: Reporting period ending 10 March 2024.
  • Apr 23, 2024
  • Communicable Diseases Intelligence
  • Viral Respiratory Diseases Epidemiology And Surveillance Team

This is the eighty-fifth and final epidemiological report for coronavirus disease 2019 (COVID-19), reported in Australia as at 23:59 Australian Eastern Daylight Time [AEST] 10 March 2024. It includes data on COVID-19 cases diagnosed in Australia.

  • Research Article
  • Cite Count Icon 2
  • 10.33321/cdi.2024.48.17
The first confirmed outbreak of chikungunya reported in Timor-Leste, 2024.
  • Apr 10, 2024
  • Communicable Diseases Intelligence
  • Filipe De Neri Machado + 19 more

Timor-Leste is a mountainous, half-island nation with a population of 1.3 million, which shares a land border with Indonesia and is 550 km from Darwin, Australia. Since independence in 2002, Timor-Leste has achieved significant development; however, high levels of poverty remain. Chikungunya virus (CHIKV) is endemic in over 100 countries in Africa, Asia, Europe and in the Americas. It is transmitted by the bite of infected Aedes aegypti or Ae. albopictus mosquitoes, which are present in Timor-Leste and which contribute to annual rainy-season dengue virus (DENV) outbreaks. Symptomatic people typically suffer from acute onset of fever, usually accompanied by severe arthritis or arthralgia. Joint pain can be debilitating for several days, and may sometimes last for weeks, months or years. Unlike DENV infection which has significant mortality, most people recover completely. Between 2002 and 2023, there were 26 cases of CHIKV notified in Australia who acquired their infection in Timor-Leste; however, laboratory testing capability for CHIKV in Timor-Leste only became available in 2021 using polymerase chain reaction (PCR). The first locally diagnosed case was notified in November 2023. In January 2024, an outbreak of CHIKV was recognised in Timor-Leste for the first time, with 195 outbreak cases reported during 1-31 January 2024; all were PCR positive. There were no cases hospitalised, and no deaths. The median age of cases was 17 years (range 1-76 years); 51% were males. Cases were reported across the country; most (88/195) were from Dili, although the highest incidence was seen in the neighbouring municipality of Ermera (monthly incidence rate of 58.8 cases per 100,000 population). This first reported outbreak of CHIKV in Timor-Leste highlights the need for improved mosquito-borne illness control and response strategies, including minimising breeding sites and promoting early presentation for treatment and differential diagnosis from DENV, and consideration of the deployment of Wolbachia-infected mosquitoes, particularly as they have shown to reduce the transmission of CHIKV, DENV and Zika virus, all of which pose threats in Timor-Leste.

  • Research Article
  • Cite Count Icon 3
  • 10.33321/cdi.2024.48.16
A brief description of the epidemiology of dengue in Dili, Timor-Leste, 2018-2022.
  • Apr 10, 2024
  • Communicable Diseases Intelligence
  • Filipe De Neri Machado + 14 more

Dengue virus (DENV) infection causes 390 million infections per year and 40,000 deaths globally. It is endemic in many countries in Asia, Africa, the Americas, the Caribbean, and Oceania. Dengue is endemic in Timor-Leste year-round, but peak transmission occurs during the rainy season. We briefly describe the epidemiology of DENV in the Municipality of Dili between 2018 and 2022. There were 6,234 cases notified, with a mean annual incidence rate of 330 cases per 100,000 population. There were 55 deaths (case fatality rate 0.9%). The peak annual incidence (3,904 cases) occurred in 2022 after an outbreak was declared in January of that year; this outbreak included 760 cases of dengue haemorrhagic fever and 35 deaths. The number of outbreak cases requiring hospital treatment exceeded the usual capacity, but facilities established for coronavirus disease 2019 (COVID-19) isolation and treatment were repurposed to meet this demand. Existing strategies of vector control, minimising breeding sites and promoting early presentation for treatment should continue, as should the utilisation of surveillance systems and treatment facilities established during the COVID-19 pandemic. However, dengue incidence remains high, and other dengue control strategies-including the deployment of Wolbachia-infected mosquitoes-should be considered in Timor-Leste.